Pretargeting of carcinomas with the avidin-biotin system

G. Paganelli, P. Magnani, F. Fazio

Research output: Contribution to journalArticle

31 Citations (Scopus)

Abstract

Diagnosis and experimental therapy of cancer have been performed with encouraging results using radiolabelled monoclonal antibodies. However, the high background due to non-specific uptake by normal tissue and blood is a major drawback in antibody-guided tumor detection. Various strategies have been proposed to overcome this problem, such as computed background subtraction, use of a second antibody, and local delivery. An antibody is a slow 'bullet' for tumor targeting, since in many lesions it requires two or three days to accumulate. The use of fragments such as F(ab')2 or Fab, which display a faster blood clearance than whole antibody, improves tumor localization to a sufficient extent (hours) to allow the use of the most suitable radionuclides, e.g. 99m-Tc. In therapeutic applications we are still far away from the optimal condition in terms of the absolute amount of radioactivity delivered to the tumor. The high specificity of antibodies could be exploited at its best by delaying the delivery of the label to a time when the ratio tumor-bound to non-tumor-bound antibody has reached its maximum value. To obtain this goal, the label should display a fast clearance and should be captured by the antibody already targeted onto tumor cells. These considerations have led to strategies of tumor pretargeting where antibody and label are administered separately. One of these strategies, based on the avidin-biotin system, has already been used extensively for several years in immunohistochemistry and in ELISA. Due to the flexibility of this system, several alternative protocols are possible. We describe a three- step and a two-step pretargeting protocol based on the avidin-biotin system.

Original languageEnglish
Pages (from-to)155-159
Number of pages5
JournalInternational Journal of Biological Markers
Volume8
Issue number3
Publication statusPublished - 1993

Fingerprint

Avidin
Biotin
Neoplasm Antibodies
Tumors
Carcinoma
Antibodies
Labels
Neoplasms
Blood
Investigational Therapies
Antibody Specificity
Radioisotopes
Radioactivity
Enzyme-Linked Immunosorbent Assay
Immunohistochemistry
Monoclonal Antibodies
Cells
Tissue

ASJC Scopus subject areas

  • Biochemistry
  • Immunology

Cite this

Pretargeting of carcinomas with the avidin-biotin system. / Paganelli, G.; Magnani, P.; Fazio, F.

In: International Journal of Biological Markers, Vol. 8, No. 3, 1993, p. 155-159.

Research output: Contribution to journalArticle

@article{57c507b9774a42798eedd684fb3a4e0f,
title = "Pretargeting of carcinomas with the avidin-biotin system",
abstract = "Diagnosis and experimental therapy of cancer have been performed with encouraging results using radiolabelled monoclonal antibodies. However, the high background due to non-specific uptake by normal tissue and blood is a major drawback in antibody-guided tumor detection. Various strategies have been proposed to overcome this problem, such as computed background subtraction, use of a second antibody, and local delivery. An antibody is a slow 'bullet' for tumor targeting, since in many lesions it requires two or three days to accumulate. The use of fragments such as F(ab')2 or Fab, which display a faster blood clearance than whole antibody, improves tumor localization to a sufficient extent (hours) to allow the use of the most suitable radionuclides, e.g. 99m-Tc. In therapeutic applications we are still far away from the optimal condition in terms of the absolute amount of radioactivity delivered to the tumor. The high specificity of antibodies could be exploited at its best by delaying the delivery of the label to a time when the ratio tumor-bound to non-tumor-bound antibody has reached its maximum value. To obtain this goal, the label should display a fast clearance and should be captured by the antibody already targeted onto tumor cells. These considerations have led to strategies of tumor pretargeting where antibody and label are administered separately. One of these strategies, based on the avidin-biotin system, has already been used extensively for several years in immunohistochemistry and in ELISA. Due to the flexibility of this system, several alternative protocols are possible. We describe a three- step and a two-step pretargeting protocol based on the avidin-biotin system.",
author = "G. Paganelli and P. Magnani and F. Fazio",
year = "1993",
language = "English",
volume = "8",
pages = "155--159",
journal = "International Journal of Biological Markers",
issn = "0393-6155",
publisher = "Wichtig Publishing Srl",
number = "3",

}

TY - JOUR

T1 - Pretargeting of carcinomas with the avidin-biotin system

AU - Paganelli, G.

AU - Magnani, P.

AU - Fazio, F.

PY - 1993

Y1 - 1993

N2 - Diagnosis and experimental therapy of cancer have been performed with encouraging results using radiolabelled monoclonal antibodies. However, the high background due to non-specific uptake by normal tissue and blood is a major drawback in antibody-guided tumor detection. Various strategies have been proposed to overcome this problem, such as computed background subtraction, use of a second antibody, and local delivery. An antibody is a slow 'bullet' for tumor targeting, since in many lesions it requires two or three days to accumulate. The use of fragments such as F(ab')2 or Fab, which display a faster blood clearance than whole antibody, improves tumor localization to a sufficient extent (hours) to allow the use of the most suitable radionuclides, e.g. 99m-Tc. In therapeutic applications we are still far away from the optimal condition in terms of the absolute amount of radioactivity delivered to the tumor. The high specificity of antibodies could be exploited at its best by delaying the delivery of the label to a time when the ratio tumor-bound to non-tumor-bound antibody has reached its maximum value. To obtain this goal, the label should display a fast clearance and should be captured by the antibody already targeted onto tumor cells. These considerations have led to strategies of tumor pretargeting where antibody and label are administered separately. One of these strategies, based on the avidin-biotin system, has already been used extensively for several years in immunohistochemistry and in ELISA. Due to the flexibility of this system, several alternative protocols are possible. We describe a three- step and a two-step pretargeting protocol based on the avidin-biotin system.

AB - Diagnosis and experimental therapy of cancer have been performed with encouraging results using radiolabelled monoclonal antibodies. However, the high background due to non-specific uptake by normal tissue and blood is a major drawback in antibody-guided tumor detection. Various strategies have been proposed to overcome this problem, such as computed background subtraction, use of a second antibody, and local delivery. An antibody is a slow 'bullet' for tumor targeting, since in many lesions it requires two or three days to accumulate. The use of fragments such as F(ab')2 or Fab, which display a faster blood clearance than whole antibody, improves tumor localization to a sufficient extent (hours) to allow the use of the most suitable radionuclides, e.g. 99m-Tc. In therapeutic applications we are still far away from the optimal condition in terms of the absolute amount of radioactivity delivered to the tumor. The high specificity of antibodies could be exploited at its best by delaying the delivery of the label to a time when the ratio tumor-bound to non-tumor-bound antibody has reached its maximum value. To obtain this goal, the label should display a fast clearance and should be captured by the antibody already targeted onto tumor cells. These considerations have led to strategies of tumor pretargeting where antibody and label are administered separately. One of these strategies, based on the avidin-biotin system, has already been used extensively for several years in immunohistochemistry and in ELISA. Due to the flexibility of this system, several alternative protocols are possible. We describe a three- step and a two-step pretargeting protocol based on the avidin-biotin system.

UR - http://www.scopus.com/inward/record.url?scp=0027380021&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0027380021&partnerID=8YFLogxK

M3 - Article

C2 - 8277207

AN - SCOPUS:0027380021

VL - 8

SP - 155

EP - 159

JO - International Journal of Biological Markers

JF - International Journal of Biological Markers

SN - 0393-6155

IS - 3

ER -